TDMS Study 05197-11 Pathology Tables
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
2 YEAR CHRONIC FINAL#1
Facility: Battelle Northwest
Chemical CAS #: 111-76-0002
Lock Date: 11/08/96
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 18 21 23 26
Natural Death 3 2 4 3
Survivors
Terminal Sacrifice 29 27 23 21
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (49) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Rectum (44) (47) (48) (47)
Intestine Large, Cecum (47) (49) (48) (48)
Intestine Small, Duodenum (49) (49) (49) (48)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (47) (49) (47) (48)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (47) (50) (47) (47)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Mesentery (12) (9) (8) (3)
Hemangioma 1 (13%)
Sex Cord Stromal Tumor, Malignant,
Metastatic, Ovary 1 (8%)
Pancreas (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Stomach, Glandular (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Bilateral, Carcinoma 1 (2%)
Adrenal Medulla (50) (50) (49) (49)
Osteosarcoma, Metastatic, Bone 1 (2%)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 3 (6%) 4 (8%) 1 (2%) 6 (12%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (49) (50)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (50) (50) (49) (49)
Histiocytic Sarcoma 1 (2%)
Pars Distalis, Adenoma 33 (66%) 32 (64%) 30 (61%) 20 (41%)
Thyroid Gland (50) (48) (49) (50)
Histiocytic Sarcoma 1 (2%)
C-Cell, Adenoma 6 (12%) 2 (4%) 5 (10%) 5 (10%)
C-Cell, Carcinoma 2 (4%) 2 (4%)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (46) (45) (44) (48)
Adenoma 6 (13%) 3 (7%) 4 (9%) 4 (8%)
Carcinoma 3 (7%) 1 (2%) 3 (7%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Ovary (50) (50) (50) (50)
Granulosa Cell Tumor Benign 1 (2%)
Granulosa-Theca Tumor Malignant 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sex Cord Stromal Tumor, Malignant 1 (2%)
Uterus (50) (50) (50) (50)
Carcinoma 1 (2%)
Deciduoma Benign 1 (2%)
Deciduoma NOS 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Page 3
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Polyp Stromal 6 (12%) 3 (6%) 5 (10%) 2 (4%)
Polyp Stromal, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Lymph Node (5) (3) (6) (2)
Histiocytic Sarcoma 1 (17%)
Renal, Histiocytic Sarcoma 1 (17%)
Renal, Osteosarcoma, Metastatic, Bone 1 (20%)
Lymph Node, Bronchial (33) (36) (34) (26)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (49) (43) (46) (46)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (48) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (38) (43) (39) (28)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Thymus (48) (47) (49) (44)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (49)
Carcinoma 3 (6%) 4 (8%) 4 (8%) 3 (6%)
Fibroadenoma 19 (38%) 16 (32%) 10 (20%) 12 (24%)
Fibroadenoma, Multiple 4 (8%) 8 (16%) 10 (20%) 3 (6%)
Histiocytic Sarcoma 1 (2%)
Skin (49) (50) (50) (50)
Basal Cell Carcinoma 1 (2%) 1 (2%)
Keratoacanthoma 2 (4%)
Squamous Cell Papilloma 2 (4%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Chordoma 1 (2%)
Osteosarcoma, Multiple 1 (2%)
Skeletal Muscle (1) (2)
Hemangioma 1 (100%)
Page 4
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - cont
Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Malignant 1 (2%)
Glioma Malignant 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Lung (50) (50) (50) (49)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%) 1 (2%)
Chordoma, Metastatic, Bone 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Nose (50) (48) (50) (49)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1)
Carcinoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sex Cord Stromal Tumor, Malignant,
Metastatic, Ovary 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Page 5
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 18 (36%) 21 (42%) 23 (46%) 24 (48%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 48 50 48
Total Primary Neoplasms 112 99 108 98
Total Animals with Benign Neoplasms 42 43 40 37
Total Benign Neoplasms 83 69 72 58
Total Animals with Malignant Neoplasms 26 26 30 32
Total Malignant Neoplasms 28 30 36 40
Total Animals with Metastatic Neoplasms 2 1 4
Total Metastatic Neoplasm 7 1 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 6 8 5 5
Moribund Sacrifice 25 31 24 21
Survivors
Terminal Sacrifice 19 11 21 24
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Intestine Large, Colon (47) (47) (47) (48)
Intestine Large, Cecum (46) (47) (47) (46)
Intestine Small, Duodenum (46) (47) (49) (49)
Intestine Small, Ileum (45) (45) (46) (47)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatocellular Carcinoma 1 (2%) 1 (2%)
Hepatocellular Adenoma 1 (2%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mesentery (8) (6) (15) (8)
Hemangiosarcoma, Metastatic, Spleen 1 (7%)
Sarcoma 1 (7%)
Sarcoma, Metastatic, Spleen 1 (7%)
Oral Mucosa (3) (1) (1)
Gingival, Fibrosarcoma 1 (100%)
Pharyngeal, Squamous Cell Papilloma 3 (100%)
Pancreas (50) (50) (50) (50)
Adenoma 1 (2%) 3 (6%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Stomach, Glandular (49) (49) (50) (50)
Tongue (1) (1)
Squamous Cell Papilloma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Adenoma 2 (4%) 1 (2%)
Carcinoma 1 (2%)
Adrenal Medulla (50) (50) (49) (50)
Pheochromocytoma Malignant 2 (4%) 3 (6%)
Pheochromocytoma Benign 12 (24%) 15 (30%) 9 (18%) 12 (24%)
Bilateral, Pheochromocytoma Benign 3 (6%) 5 (10%) 4 (8%) 4 (8%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 5 (10%) 2 (4%) 3 (6%) 3 (6%)
Adenoma, Multiple 1 (2%) 1 (2%)
Carcinoma 4 (8%) 1 (2%) 3 (6%)
Pituitary Gland (49) (49) (48) (47)
Pars Distalis, Adenoma 24 (49%) 29 (59%) 24 (50%) 25 (53%)
Thyroid Gland (50) (46) (48) (48)
C-Cell, Adenoma 7 (14%) 3 (7%) 7 (15%) 10 (21%)
C-Cell, Carcinoma 1 (2%) 3 (6%) 2 (4%)
Follicular Cell, Adenoma 1 (2%) 3 (6%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2) (1)
Tissue NOS (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Preputial Gland (46) (47) (50) (43)
Adenoma 3 (7%) 1 (2%) 5 (10%) 5 (12%)
Carcinoma 5 (11%) 1 (2%) 2 (4%) 1 (2%)
Prostate (49) (49) (50) (50)
Adenoma 1 (2%) 4 (8%) 1 (2%)
Adenoma, Multiple 1 (2%)
Seminal Vesicle (47) (44) (46) (48)
Adenoma 1 (2%)
Testes (50) (50) (50) (50)
Bilateral, Interstitial Cell, Adenoma 34 (68%) 38 (76%) 36 (72%) 31 (62%)
Interstitial Cell, Adenoma 7 (14%) 4 (8%) 8 (16%) 10 (20%)
Page 9
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (49)
Lymph Node (10) (10) (8) (10)
Sarcoma, Metastatic, Skin 1 (10%)
Lymph Node, Bronchial (36) (38) (41) (34)
Lymph Node, Mandibular (44) (47) (47) (46)
Lymph Node, Mesenteric (50) (49) (50) (50)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Sarcoma, Metastatic, Spleen 1 (2%)
Lymph Node, Mediastinal (44) (44) (45) (44)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Spleen (50) (50) (50) (50)
Fibroma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Sarcoma 1 (2%) 1 (2%)
Thymus (45) (44) (44) (39)
Thymoma Malignant 1 (2%) 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (44) (40) (44) (45)
Carcinoma 1 (3%)
Fibroadenoma 2 (5%) 1 (3%) 3 (7%) 1 (2%)
Fibroadenoma, Multiple 1 (2%)
Skin (50) (50) (50) (50)
Basal Cell Adenoma 2 (4%) 1 (2%)
Basal Cell Carcinoma 2 (4%) 1 (2%)
Keratoacanthoma 3 (6%) 3 (6%) 4 (8%) 2 (4%)
Keratoacanthoma, Multiple 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 4 (8%) 1 (2%)
Sebaceous Gland, Adenoma 2 (4%)
Subcutaneous Tissue, Fibroma 2 (4%) 2 (4%) 2 (4%) 3 (6%)
Subcutaneous Tissue, Fibroma, Multiple 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%) 1 (2%)
Skeletal Muscle (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Benign 1 (2%)
Astrocytoma Malignant 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Glioma Malignant 2 (4%)
Meningioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%) 4 (8%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Carcinoma, Metastatic, Preputial Gland 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%) 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Nose (48) (49) (49) (50)
Lateral Wall, Adenoma 1 (2%)
Turbinate, Chondroma 1 (2%)
Pleura (1)
Trachea (50) (49) (50) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1) (2)
Carcinoma 1 (100%) 1 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Mesenchymal Tumor Malignant 1 (2%)
Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%) 2 (4%)
Renal Tubule, Oncocytoma Benign 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
Urinary Bladder (49) (50) (50) (50)
Transitional Epithelium, Papilloma 2 (4%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leukemia Mononuclear 29 (58%) 31 (62%) 33 (66%) 30 (60%)
Lymphoma Malignant 1 (2%)
Mesothelioma Benign 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Mesothelioma Malignant 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05197-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 02/16/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:13:51
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 31.2 PPM 62.5 PPM 125 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 50 50 50
Total Primary Neoplasms 173 161 187 163
Total Animals with Benign Neoplasms 49 49 49 49
Total Benign Neoplasms 123 114 131 119
Total Animals with Malignant Neoplasms 40 40 41 38
Total Malignant Neoplasms 50 47 56 44
Total Animals with Metastatic Neoplasms 3 3 3 2
Total Metastatic Neoplasm 4 3 8 3
Total Animals with Malignant Neoplasms 2 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------